NAFLD: Mechanisms, Treatments, and Biomarkers
Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic-associated fatty liver disease (MAFLD), is one of the most common causes of liver diseases worldwide. NAFLD is growing in parallel with the obesity epidemic. No pharmacological treatment is available to treat NAFLD, specifically. T...
Main Author: | Fatiha Nassir |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/12/6/824 |
Similar Items
-
Treatments for NAFLD: State of Art
by: Alessandro Mantovani, et al.
Published: (2021-02-01) -
MAFLD and CKD: An Updated Narrative Review
by: Alessandro Mantovani, et al.
Published: (2022-06-01) -
Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the pastKey points
by: Oyekoya T. Ayonrinde
Published: (2021-06-01) -
COVID-19 and MAFLD/NAFLD: An updated review
by: Ali Nowroozi, et al.
Published: (2023-03-01) -
The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
by: Yvonne Burmeister, et al.
Published: (2023-12-01)